PD1 Combined With Apatinib in Patients With Relapsed or Refractory NK/T Cell Lymphoma
Status:
Unknown status
Trial end date:
2021-06-30
Target enrollment:
Participant gender:
Summary
This is an open-label, single-center, nonrandomized, Phase 2 study to evaluate efficacy and
safety of SHR-1210 combined with Apatinib in subjects with relapsed or refractory NK/T cell
lymphoma.Efficacy will be assessed every 8 weeks according to 2014 Lugano criteria.Safety
evaluations (both clinical and laboratory) are performed at baseline, before each study
treatment, and throughout the study.